These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 1616860)

  • 41. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
    Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantitative oestrogen and progesterone receptor values in primary breast cancer and predictability of response to endocrine therapy.
    Fernandez MD; Alaghband-Zadeh J; Burn JI
    Clin Oncol; 1983 Sep; 9(3):245-50. PubMed ID: 6616999
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Receptor status (ER and PgR) determined with histochemical and biochemical methods in breast carcinoma].
    Simone G; Paradiso A; Cirillo R; Mangia A; Rella G; Wiesel S; Petroni S; De Benedictis G; De Lena M
    Pathologica; 1991; 83(1086):449-59. PubMed ID: 1724316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
    Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation.
    Andersen J; Bentzen SM; Poulsen HS
    Eur J Cancer Clin Oncol; 1988 Mar; 24(3):377-84. PubMed ID: 3289941
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of cytosol CA15-3, carcinoembryonic antigen, estrogen and progesterone receptors in breast cancer tissues.
    Miya T; Watanabe T; Adachi I; Itabashi M; Fukutomi T; Yamaguchi K; Abe K; Arakawa M
    Jpn J Cancer Res; 1992 Feb; 83(2):171-7. PubMed ID: 1555999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunohistological demonstration of progesterone receptor in breast carcinomas: correlation with radioligand binding assays and oestrogen receptor immunohistology.
    Giri DD; Goepel JR; Rogers K; Underwood JC
    J Clin Pathol; 1988 Apr; 41(4):444-7. PubMed ID: 3366932
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunocytochemical analysis of hormone receptors with malignant cells separated from human mammary tumors.
    Gaffney EV; Halpin DP; Moody WE; Elliott CB
    Am J Clin Pathol; 1994 Jul; 102(1):68-71. PubMed ID: 8037169
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of steroid hormone sensitivity in human breast cancers maintained ex vivo under organotypical culture conditions.
    Darro F; Schwarz G; Pétein M; Schwarz S; Chaboteaux C; Nogaret JM; Decaestecker C; Salmon I; Kiss R
    J Cancer Res Clin Oncol; 2000 May; 126(5):257-62. PubMed ID: 10815760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group.
    Ahmed SS; Thike AA; Zhang K; Lim JC; Tan PH
    J Clin Pathol; 2017 Apr; 70(4):320-326. PubMed ID: 27612503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hormonal receptor determination of 1,052 Chinese breast cancers.
    Chow LW; Ho P
    J Surg Oncol; 2000 Nov; 75(3):172-5. PubMed ID: 11088048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estrogen and progesterone receptors in human meningiomas: biochemical and immunocytochemical evaluation.
    Bozzetti C; Camisa R; Nizzoli R; Manotti L; Guazzi A; Naldi N; Mazza S; Nizzoli V; Cocconi G
    Surg Neurol; 1995 Mar; 43(3):230-3; discussion 234. PubMed ID: 7792684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: prognostic significance.
    Layfield LJ; Saria EA; Conlon DH; Kerns BJ
    J Surg Oncol; 1996 Mar; 61(3):177-84. PubMed ID: 8637203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer.
    Paradiso A; Tommasi S; Mangia A; Lorusso V; Simone G; De Lena M
    Cancer Res; 1990 May; 50(10):2958-62. PubMed ID: 2334898
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.
    Bogina G; Lunardi G; Coati F; Zamboni G; Gori S; Bortesi L; Marconi M; Cassandrini PA; Turazza M; Cortesi L; DeMatteis E; Ficarra G; Ibrahim T; Serra P; Medri L; Giraudi S; Lambertini M; Carli F; Foglietta J; Sidoni A; Nunzi M; Ficorella C; Diadema MR; Del Mastro L
    Tumori; 2015; 101(4):398-403. PubMed ID: 26045108
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Premorbid body weight and its relations to primary tumour diameter in breast cancer patients; its dependence on estrogen and progesteron receptor status.
    Maehle BO; Tretli S; Skjaerven R; Thorsen T
    Breast Cancer Res Treat; 2001 Jul; 68(2):159-69. PubMed ID: 11688519
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Natural history of estrogen receptor-negative, progesterone receptor-positive breast cancer.
    Nikolic-Vukosavljevic D; Kanjer K; Neskovic-Konstantinovic Z; Vukotic D
    Int J Biol Markers; 2002; 17(3):196-200. PubMed ID: 12408471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.